Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database
Open accessAbstract
WHAT IS KNOWN AND OBJECTIVE: Glucagon-like peptide-1 (GLP-1) receptor agonists delay gastric and bowel emptying. A similar inhibitory effect of GLP-1 on gallbladder motility has been suggested, possibly leading to an increased risk of cholecystitis related to incretin-based medications, which include GLP-1 antagonists. Our objective was to review evidence in EudraVigilance, the European spontaneous reporting database and the scientific literature on this issue. COMMENT: Increasing evidence suggests an association of incretins with gallbladder adverse events. Pharmacovigilance data from EudraVigilance includes 200 serious ADR reports concerning cholecystitis related to the use of incretin-based therapies. Several mechanisms may explain this increased risk of cholecystitis, including rapid weight loss, inhibition of gallbladder contraction and emptying, reduced bile acids production, modulation of inflammation. WHAT IS NEW AND CONCLUSIONS: The available data suggest the possibility of gallbladder disease in diabetic subjects treated with incretins and highlight the importance of evaluating risk factors for cholelithiasis and gallbladder diseases in patients with diabetes before starting this therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Based on adverse events in the European EudraVigilance database, gallbladder disease is likely not limited to liraglutide but affects all incretin-based therapies.
“Based on AEs as reported in the European EudraVigilance database, gallbladder disease is likely not limited to liraglutide, but affects all incretin-based therapies”
From Safety of Semaglutide (2021) · cites this paper as [85]
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Willemen, M. J. C., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Meyboom, R. H., Egberts, T. C. G., & Leufkens, H. G. M. (2011) · Diabetes Care · doi:10.2337/dc10-1771 · Cited by 140 · see citing works
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138 · see citing works
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
Keller, J., Trautmann, M. E., Haber, H., Tham, L. S., Hunt, T., Mace, K., & Linnebjerg, H. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.005 · Cited by 61 · see citing works
Reinhold, D., Biton, A., Goihl, A., Pieper, S., Lendeckel, U., Faust, J., Neubert, K., Bank, U., Täger, M., Ansorge, S., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1423.042 · Cited by 58 · see citing works
Effect of Circulating Peptide YY on Gallbladder Emptying in Humans
Hoentjen, F. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655201750422710 · Cited by 52 · see citing works
Montilla, S., Marchesini, G., Sammarco, A., Trotta, M. P., Siviero, P. D., Tomino, C., Melchiorri, D., & Pani, L. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.07.014 · Cited by 46 · see citing works
Gurney, K., MacConell, L., Malloy, J. L., Zhou, M., & Kolterman, O. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s77290 · Cited by 45 · see citing works
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 32 · see citing works
Roshanov, P. S., & Dennis, B. B. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.014 · Cited by 26 · see citing works
Factors affecting gallbladder motility: drugs.
Marzio, L. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00088-4 · Cited by 19 · see citing works
Shlomo, S. B., Zvibel, I., Rabinowich, L., Goldiner, I., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2353-7 · Cited by 17 · see citing works
Liraglutide-related cholelithiasis
Korkmaz, H., Araz, M., Alkan, S., & Akarsu, E. (2015) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0335-2 · Cited by 13 · see citing works
Ben‐Shlomo, S., Zvibel, I., Rabinowich, L., Goldiner, I., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2455-2 · Cited by 13 · see citing works
Sahoo, J., Kamalanathan, S., Vivekanandan, M., & Swaminathan, R. P. (2015) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.162016 · Cited by 2 · see citing works
Flagged first, then by citations
1 of the 17 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · see citing works
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332 · see citing works
Self-citationAdverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145 · see citing works
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. M. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 131 · see citing works
Nauck, M. A., Muus Ghorbani, M. L., Kreiner, E., Saevereid, H. A., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2019) · Diabetes Care · doi:10.2337/dc19-0415 · Cited by 69 · see citing works
Lim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 68 · see citing works
Gether, I. M., Nexøe-Larsen, C., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01008 · Cited by 56 · see citing works
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61 · see citing works
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., Nieuwdorp, M., Groen, A. K., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12748 · Cited by 56 · see citing works
Self-citationNexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51 · see citing works
Sim, R., Chong, C. W., Loganadan, N. K., Fong, A. Y. Y., Navaravong, L., Hussein, Z. B., Khunti, K. K., & Lee, S. W. H. (2021) · Diabetic Medicine · doi:10.1111/dme.14780 · Cited by 34 · see citing works
Hinnen, D., & Strong, J. L. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0014 · Cited by 24 · see citing works
Shaddinger, B. C., Young, M. A., Billiard, J., Collins, D. A., Hussaini, A., & Nino, A. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.940 · Cited by 22 · see citing works
A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
Du, Y., Zhang, M., Wang, Z., Hu, M., Xie, D., Wang, X., Guo, Z., Zhu, J., Zhang, W., Luo, Z., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14229 · Cited by 21 · see citing works
Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
Gaw, C. E., Hays, H. L., Kemp, C. A., Kistamgari, S., Spiller, H. A., Rine, N. I., Rhodes, A. L., Zhu, M., & Smith, G. A. (2024) · Journal of Medical Toxicology · doi:10.1007/s13181-024-00999-x · Cited by 18 · see citing works
Dong, Y., Wu, J., Chang, C., Lin, J., Wu, L., & Toh, S. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2688 · Cited by 16 · see citing works
Zonoozi, S. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2017.004 · Cited by 9 · see citing works
Shapiro, S. B., Yin, H., Yu, O. H. Y., & Azoulay, L. (2024) · Drug Safety · doi:10.1007/s40264-024-01434-4 · Cited by 7 · see citing works
Yu, M., Yang, Z., Chen, C., Lv, Y., Xiang, L., Zhao, S., & Li, R. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00924-8 · Cited by 6 · see citing works
Liang, Y., Zhang, Z., Zheng, J., Wang, Y., He, J., Zhao, J., & Su, L. (2024) · Endocrine Connections · doi:10.1530/ec-24-0404 · Cited by 4 · see citing works
Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy
Butler, J., Bjurstrom, M., & Marceau, A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab045 · Cited by 3 · see citing works
Eldesouki, M. H., Alkasabrah, O., Kloub, M., Abosheaishaa, H. M., Elfert, K., Sharma, A., Andrawes, S., & Duong, N. K. (2026) · United European Gastroenterology Journal · doi:10.1002/ueg2.70238 · Cited by 2 · see citing works
Semaglutide versus liraglutide for treatment of obesity
Mikhail, N. E. (2021) · doi:10.32474/ado.2021.03.000162 · Cited by 1 · see citing works
Once weekly semaglutide for treatment of obesity
Mikhail, N. E. (2021) · Journal of Clinical and Laboratory Research · doi:10.31579/2768-0487/015
(2016) · Reactions Weekly · doi:10.1007/s40278-016-18128-x
Yu, M., Yang, Z., Chen, C., Lv, Y., Xiang, L., Zhao, S., & Li, R. (2022) · Figshare · doi:10.6084/m9.figshare.21383027
Yu, M., Yang, Z., Chen, C., Lv, Y., Xiang, L., Zhao, S., & Li, R. (2022) · Figshare · doi:10.6084/m9.figshare.21383030
Yu, M., Yang, Z., Chen, C., Lv, Y., Xiang, L., Zhao, S., & Li, R. (2022) · Figshare · doi:10.6084/m9.figshare.21383036
Yu, M., Yang, Z., Chen, C., Lv, Y., Xiang, L., Zhao, S., & Li, R. (2022) · Figshare · doi:10.6084/m9.figshare.21383024
Yu, M., Yang, Z., Chen, C., Lv, Y., Xiang, L., Zhao, S., & Li, R. (2022) · Figshare · doi:10.6084/m9.figshare.21383033
- Authors
- Pizzimenti, V., Giandalia, A., Cucinotta, D., Russo, G. T., Smits, M., Cutroneo, P. M., & Trifirò, G.
- Affiliations
- University of Messina (IT)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" (IT)
- Corresponding author
- Cutroneo, P. M.
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2016-03-02
- Volume
- 41
- Issue
- 2
- Pages
- 116-118
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W2290082435
- Cited by
- 30
- References
- 17
- Citations by year
- 2026: 1 · 2024: 5 · 2022: 8 · 2021: 5 · 2020: 1 · 2019: 1 · 2018: 4 · 2017: 1 · 2016: 4
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Pharmacy and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gallbladder and Bile Duct Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- incretin-based therapy, acute cholecystitis, GLP-1 receptor agonists, GLP-1 receptor antagonists, gallbladder motility, gallbladder disease, gallstones, adverse drug reactions, pharmacovigilance, diabetes mellitus, rapid weight loss, bile acid synthesis
- MeSH terms
- Humans, Databases, Factual, Adverse Drug Reaction Reporting Systems, Cholecystitis, Acute, Glucagon-Like Peptide 1, Incretins, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
